434
Participants
Start Date
December 17, 2020
Primary Completion Date
January 20, 2023
Study Completion Date
January 20, 2023
MF/IND/GLY plus sensor system
"There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled.~Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label."
FDC therapy
There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Fürstenwalde
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Papenburg
Novartis Investigative Site, Hanover
Novartis Investigative Site, Hanover
Novartis Investigative Site, Burgwedel
Novartis Investigative Site, Marburg
Novartis Investigative Site, Bad Sachsa
Novartis Investigative Site, Einbeck
Novartis Investigative Site, Braunschweig
Novartis Investigative Site, Ibbenbueren
Novartis Investigative Site, Aschaffenburg
Novartis Investigative Site, Wiesbaden
Novartis Investigative Site, Augsburg
Novartis Investigative Site, Ulm
Novartis Investigative Site, Ansbach
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Göttingen
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Markkleeberg
Novartis Investigative Site, Radebeul
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY